The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

April 16 (Reuters) - Abbott marginally beat Wall Street estimates for quarterly profit and ‌revenue on Thursday, partially helped ‌by its newly acquired cancer diagnostics business.

However, its shares ​were down 2% before the bell, after the company said its 2026 profit forecast will see a 20 cent hit due ‌to its recent $23 ⁠billion acquisition of cancer test maker Exact Sciences.

The medical device maker ⁠expects adjusted profit per share between $5.38 to $5.58 for 2026, compared with its previous ​forecast of $5.55 ​to $5.80 per share.

Despite ​the hit, CEO Robert ‌Ford said the acquisition of Exact Sciences adds another high-growth business to the company's portfolio.

The company also benefited from continued strength in its medical device unit, its ‌largest in terms of ​revenue.

On an adjusted basis, the ​company reported ​first-quarter profit per share of $1.15, ‌compared with analysts' estimate ​of $1.14, according ​to data compiled by LSEG.

Total revenue came in at $11.16 billion in the first ​quarter, compared ‌with expectations of $11 billion.

(Reporting by Siddhi ​Mahatole and Puyaan Singh in Bengaluru; ​Editing by Devika Syamnath)